{"id":"https://openalex.org/W2005461786","doi":"https://doi.org/10.1177/1533034615574386","title":"Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer","display_name":"Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer","publication_year":2015,"publication_date":"2015-03-10","ids":{"openalex":"https://openalex.org/W2005461786","doi":"https://doi.org/10.1177/1533034615574386","mag":"2005461786","pmid":"https://pubmed.ncbi.nlm.nih.gov/25759424"},"language":"en","primary_location":{"id":"doi:10.1177/1533034615574386","doi":"https://doi.org/10.1177/1533034615574386","is_oa":false,"landing_page_url":"https://doi.org/10.1177/1533034615574386","pdf_url":null,"source":{"id":"https://openalex.org/S2955411","display_name":"Technology in Cancer Research & Treatment","issn_l":"1533-0338","issn":["1533-0338","1533-0346"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Technology in Cancer Research &amp; Treatment","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4565779","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034645022","display_name":"Nils D. Arvold","orcid":"https://orcid.org/0009-0001-1038-1930","observed_orcids":["https://orcid.org/0009-0001-1038-1930"]},"institutions":[{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nils D. Arvold","raw_affiliation_strings":["Department of Radiation Oncology, Dana-Farber/Brigham & Women\u2019s Cancer Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Dana-Farber/Brigham & Women\u2019s Cancer Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007635741","display_name":"Pedram Heidari","orcid":"https://orcid.org/0000-0001-6383-465X","observed_orcids":["https://orcid.org/0000-0001-6383-465X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pedram Heidari","raw_affiliation_strings":["Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054853074","display_name":"Anchisa Kunawudhi","orcid":"https://orcid.org/0000-0002-9393-9572","observed_orcids":["https://orcid.org/0000-0002-9393-9572"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anchisa Kunawudhi","raw_affiliation_strings":["Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075333926","display_name":"Lecia Van Dam Sequist","orcid":"https://orcid.org/0000-0002-8965-6991","observed_orcids":["https://orcid.org/0000-0002-8965-6991"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lecia V. Sequist","raw_affiliation_strings":["Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063494562","display_name":"Umar Mahmood","orcid":"https://orcid.org/0000-0001-7414-6123","observed_orcids":["https://orcid.org/0000-0001-7414-6123"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Umar Mahmood","raw_affiliation_strings":["Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034645022"],"corresponding_institution_ids":["https://openalex.org/I4210161994"],"apc_list":{"value":2650,"currency":"USD","value_usd":2650},"apc_paid":null,"fwci":0.8832,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.68760444,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"15","issue":"2","first_page":"234","last_page":"242"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.6161999702453613,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.6161999702453613,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10522","display_name":"Medical Imaging Techniques and Applications","score":0.19169999659061432,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0940999984741211,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.8999999761581421},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.890999972820282},{"id":"https://openalex.org/keywords/fmiso-pet","display_name":"FMISO PET","score":0.7860000133514404},{"id":"https://openalex.org/keywords/fluoromisonidazole","display_name":"fluoromisonidazole","score":0.8460000157356262},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.7910000085830688},{"id":"https://openalex.org/keywords/standardized-uptake-value","display_name":"standardized uptake value","score":0.7129999995231628},{"id":"https://openalex.org/keywords/tumor-response-assessment","display_name":"tumor response assessment","score":0.5529999732971191},{"id":"https://openalex.org/keywords/hypoxia-imaging","display_name":"hypoxia imaging","score":0.5230000019073486},{"id":"https://openalex.org/keywords/metastatic-lung-cancer","display_name":"metastatic lung cancer","score":0.675000011920929},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6859999895095825},{"id":"https://openalex.org/keywords/treatment-response-monitoring","display_name":"treatment response monitoring","score":0.5809999704360962},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.3709999918937683},{"id":"https://openalex.org/keywords/radiotherapy-resistance","display_name":"radiotherapy resistance","score":0.9380000233650208}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9023431539535522},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7870784997940063},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6794157028198242},{"id":"https://openalex.org/C7836513","wikidata":"https://www.wikidata.org/wiki/Q1641506","display_name":"Hypoxia (environmental)","level":3,"score":0.5915372967720032},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5693081021308899},{"id":"https://openalex.org/C199374082","wikidata":"https://www.wikidata.org/wiki/Q907080","display_name":"Standardized uptake value","level":3,"score":0.537082850933075},{"id":"https://openalex.org/C2779081379","wikidata":"https://www.wikidata.org/wiki/Q7852677","display_name":"Tumor hypoxia","level":3,"score":0.5159640908241272},{"id":"https://openalex.org/C2775842073","wikidata":"https://www.wikidata.org/wiki/Q208376","display_name":"Positron emission tomography","level":2,"score":0.4783846139907837},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4716935455799103},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4662555456161499},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.4642302393913269},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.4629583954811096},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.4354768991470337},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.394130140542984},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.3358456790447235},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30432388186454773},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10610881447792053},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0757511556148529},{"id":"https://openalex.org/C540031477","wikidata":"https://www.wikidata.org/wiki/Q629","display_name":"Oxygen","level":2,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008920","descriptor_name":"Misonidazole","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D008920","descriptor_name":"Misonidazole","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D008920","descriptor_name":"Misonidazole","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D008920","descriptor_name":"Misonidazole","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008920","descriptor_name":"Misonidazole","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008920","descriptor_name":"Misonidazole","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015687","descriptor_name":"Cell Hypoxia","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015687","descriptor_name":"Cell Hypoxia","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015687","descriptor_name":"Cell Hypoxia","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049268","descriptor_name":"Positron-Emission Tomography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049268","descriptor_name":"Positron-Emission Tomography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049268","descriptor_name":"Positron-Emission Tomography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1177/1533034615574386","doi":"https://doi.org/10.1177/1533034615574386","is_oa":false,"landing_page_url":"https://doi.org/10.1177/1533034615574386","pdf_url":null,"source":{"id":"https://openalex.org/S2955411","display_name":"Technology in Cancer Research & Treatment","issn_l":"1533-0338","issn":["1533-0338","1533-0346"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Technology in Cancer Research &amp; Treatment","raw_type":"journal-article"},{"id":"pmid:25759424","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25759424","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Technology in cancer research & treatment","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4565779","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4565779","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Technol Cancer Res Treat","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4565779","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4565779","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Technol Cancer Res Treat","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8299999833106995}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1119066253","display_name":"Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer","funder_award_id":"P50CA127003","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2301068275","display_name":null,"funder_award_id":"U01 CA143056","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7027595435","display_name":"Mouse Models for Human Cancer","funder_award_id":"U01CA084301","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W27437349","https://openalex.org/W1682474579","https://openalex.org/W1890605084","https://openalex.org/W1983312064","https://openalex.org/W2020830322","https://openalex.org/W2021381932","https://openalex.org/W2028999918","https://openalex.org/W2043696829","https://openalex.org/W2043911313","https://openalex.org/W2053246366","https://openalex.org/W2053846938","https://openalex.org/W2060426390","https://openalex.org/W2096441944","https://openalex.org/W2101282575","https://openalex.org/W2101329867","https://openalex.org/W2101995865","https://openalex.org/W2106787323","https://openalex.org/W2108733591","https://openalex.org/W2112964045","https://openalex.org/W2118981922","https://openalex.org/W2120718661","https://openalex.org/W2125149985","https://openalex.org/W2133138712","https://openalex.org/W2136579332","https://openalex.org/W2139236349","https://openalex.org/W2146404049","https://openalex.org/W2148346100","https://openalex.org/W2155977433","https://openalex.org/W2158453396","https://openalex.org/W2161821474","https://openalex.org/W2198589685","https://openalex.org/W2478740916","https://openalex.org/W7005515419"],"related_works":["https://openalex.org/W1994763147","https://openalex.org/W2120992361","https://openalex.org/W2023597833","https://openalex.org/W2076668512","https://openalex.org/W2541392164","https://openalex.org/W2360123363","https://openalex.org/W2168841302","https://openalex.org/W2896649837","https://openalex.org/W2035762060","https://openalex.org/W2103997800"],"abstract_inverted_index":{"Hypoxia":[0],"is":[1,44,311],"associated":[2],"with":[3,36,82,119,140,203,224,251,273],"resistance":[4],"to":[5,56,73,111,150,161,211,313,324],"radiotherapy":[6],"and":[7,26,92,103,130,148,192,199],"chemotherapy.":[8],"Functional":[9],"imaging":[10,221,319],"of":[11,23,105,178,182,227,321],"hypoxia":[12,39,68,301],"in":[13,40,51,67,69,71,114,125,157,300,306],"non-small":[14],"cell":[15],"lung":[16,85],"cancer":[17],"(NSCLC)":[18],"could":[19,64],"allow":[20],"early":[21,322],"assessment":[22],"tumor":[24],"response":[25,72,323],"guide":[27],"subsequent":[28],"therapies.":[29],"Epidermal":[30],"growth":[31],"factor":[32],"receptor":[33],"(EGFR)":[34],"inhibition":[35],"erlotinib":[37,96,154,172,231],"reduces":[38],"vivo.":[41],"[18F]-Fluoromisonidazole":[42],"(FMISO)":[43],"a":[45,77,133],"radiolabeled":[46],"tracer":[47],"that":[48,295],"selectively":[49],"accumulates":[50],"hypoxic":[52],"cells.":[53],"We":[54],"sought":[55],"determine":[57,314],"whether":[58],"FMISO":[59,228],"positron":[60],"emission":[61],"tomography":[62,165],"(FMISO-PET)":[63],"detect":[65,298],"changes":[66,113,299],"vivo":[70],"EGFR-targeted":[74],"therapy.":[75,326],"In":[76,132,241,263,291],"preclinical":[78,219],"investigation,":[79],"nude":[80],"mice":[81,124],"human":[83,137],"EGFR-mutant":[84,141,307],"adenocarcinoma":[86],"xenografts":[87,184],"underwent":[88,144],"FMISO-PET":[89,145,296],"scans":[90,146,167],"before":[91,147],"5":[93],"days":[94,152],"after":[95,153,171,230,249,260,271,303],"or":[97],"empty":[98],"vehicle":[99],"initiation.":[100,155,173,232],"Descriptive":[101],"statistics":[102],"analysis":[104],"variance":[106],"(ANOVA)":[107],"tests":[108],"were":[109,159,222,235],"used":[110],"analyze":[112],"standardized":[115],"uptake":[116,229],"value":[117],"(SUV),":[118],"pooled":[120],"analyses":[121],"for":[122,196],"the":[123,179,183,207,238,242,264,283],"each":[126],"group":[127,209],"(baseline,":[128],"postvehicle,":[129,198],"posterlotinib).":[131],"small":[134],"correlative":[135],"pilot":[136,239],"study,":[138],"patients":[139,234],"metastatic":[142],"NSCLC":[143],"10":[149],"12":[151],"Changes":[156,217],"SUV":[158],"compared":[160,210],"standard":[162],"chest":[163,255,277],"computed":[164],"(CT)":[166],"performed":[168],"6":[169],"weeks":[170],"The":[174],"mean":[175],"(\u00b1standard":[176],"error":[177],"mean;":[180],"SUVmean)":[181],"was":[185],"0.17":[186],"\u00b1":[187,190,194],"0.014,":[188],"0.14":[189],"0.008,":[191],"0.06":[193],"0.004":[195],"baseline,":[197],"posterlotinib":[200,208],"groups,":[201],"respectively,":[202],"lower":[204],"SUVmean":[205,245,267],"among":[206],"other":[212],"groups":[213],"(P":[214],"<":[215],".05).":[216],"on":[218,237,253,275],"PET":[220],"striking,":[223],"near-complete":[225],"disappearance":[226],"Two":[233],"enrolled":[236],"study.":[240],"first":[243],"patient,":[244,266],"increased":[246],"by":[247,258,269,280],"21%":[248],"erlotinib,":[250,272],"progression":[252],"6-week":[254,276],"CT":[256,278],"followed":[257],"death":[259],"4.8":[261],"months.":[262,290],"second":[265],"decreased":[268],"7%":[270],"regression":[274],"accompanied":[279],"clinical":[281],"improvement;":[282],"patient":[284],"had":[285],"stable":[286],"disease":[287],"at":[288],"14.5":[289],"conclusion,":[292],"we":[293],"observed":[294],"can":[297],"levels":[302],"EGFR-directed":[304,325],"therapy":[305],"NSCLC.":[308],"Further":[309],"study":[310],"warranted":[312],"its":[315],"utility":[316],"as":[317],"an":[318],"biomarker":[320]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}